B-Tech Consulting, Ltd.
B-Tech was started in 2008 as a consulting company providing both business and technical advice and analytical services to the academic, pharmaceutical, and biotechnology communities. Within a year the business had evolved to focus on providing contract research and outsourcing capabilities to these organizations. With the dramatic changes to the pharmaceutical industry, the approach towards building a business around the contract research capabilities has proved successful.
Today B-Tech provides a variety of services, all focused on computational approaches to drug discovery and biological research. We have strategic collaborations with academic colleagues at Stanford University, Drexel University, University of Missouri-Kansas City, University of Michigan, University of Pennsylvania, and Temple University. As a small company we often leverage those collaborations to enhance our capabilities and provide significant additional resources and knowledge to our clients.
We maintain in-house programming capabilities and computational infrastructure, primarily focused on our cheminformatics platform for drug discovery, and for our HIPAA-compliant clinical data repositories that we maintain for clients. We also maintain an extensive inventory of both proprietary and commercial software tools for data analysis, management, and reporting.
B-Tech is fortunate to receive NIH funding for internal projects through the Small Business Innovation Research (SBIR) program, as well as through collaborative grants through traditional academic funding mechanisms. We believe that good science remains the key to success.
Brian Moldover, Ph.D., President
Dr Moldover received his Ph.D. in molecular genetics in 1991 from Temple University, and has 17 years experience in the Biotechnology/Pharmaceutical industry. He has managed research and technology in Genomics, Bioinformatics, and Research IT at major pharmaceutical companies, including Warner-Lambert, Pfizer, Aventis, and Schering AG. He has also held academic positions at the National Institutes of Health.
His scientific expertise lies primarily in the fields of genomics and bioinformatics. His industrial research was focused on the identification of new drug targets through the use of microarrays, DNA sequencing, and genetic analysis using computational approaches.
As management and senior management he has overseen a staff of over 50 scientists and IT engineers, and managed multinational budgets in excess of $30MM. He has been responsible for setting and implementing strategic corporate direction and policy.
He brings significant experience in budget and personnel management, business development, contract negotiation, and technology development, acquisition, and deployment.
Contract Research and Project Support
Biotechnology/Pharmaceutical Business Services